BioCentriq has appointed Syed T. Husain as its new Chief Executive Officer (CEO) and a member of the Board of Directors, marking a new chapter in the company’s growth in the cell and gene therapy (CGT) sector. Husain, a veteran
BioCentriq, a cell therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant enhancement to its partnership with Pluristyx Inc., an early-stage biotechnology company specialising in Induced Pluripotent Stem Cell (iPSC) products. Pluristyx’s unique clinical-grade iPSC lines, derived from
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
